Drug profile

The FDA adverse-event record for Flea Prevention

21 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Flea Prevention. Species, reactions, and outcomes follow.

#1743 of 2,679
by report volume (all drugs)
21
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Flea Prevention ranks #1727 of 2679 by total reports (21). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1727
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Flea Prevention has 21 reports now versus 21 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Flea Prevention changes

Signature read: Flea Prevention's 0.0% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
0
Deaths Reported
0.0%
Death-coded share of reports

Active Ingredients

Flea Prevention

Administration Routes

UnknownOralTopical

Species Affected

Dog 12
Cat 9

Most Affected Breeds

Domestic Shorthair 7
Dog (unknown) 3
Retriever - Golden 2
Cat (unknown) 2
Poodle - Toy 1
Pointing Dog - German Short-haired 1
Spitz - German Pomeranian 1
Boxer (German Boxer) 1
Chinese Crested Dog (unspecified) 1
Bulldog - French 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 7
Itching 3
Vomiting 3
Licking 2
Seizure NOS 2
Lack of efficacy (endoparasite) - tapeworm 2
Alopecia local 2
Pustules 1
Mucous stool 1
Blood in faeces 1
Other abnormal test result NOS 1
Self trauma 1

Outcome Breakdown

Outcome Unknown
11 (52.4%)
Ongoing
9 (42.9%)
Recovered/Normal
1 (4.8%)

Flea Prevention: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Flea Prevention (#1743 of 2,679 by report volume); death-coded 0.0%. PlainBreed drug row · death-coded share stamp 0.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →